Next Article Table of Contents

Perspective

Discovering Nature's Diverse Pathways to Vitamin B₁₂: A 35-Year Odyssey

A. Ian Scott

Center for Biological NMR, Chemistry Department, Texas A&M University, 3255 TAMU, College Station, Texas 77843-3255

J. Org. Chem., 2003, 68 (7), pp 2529–2539

DOI: 10.1021/jo020728t

Publication Date (Web): March 28, 2003

aiscott@tamu.edu

Abstract

The chronology of the discoveries along the pathway of vitamin B₁₂ biosynthesis is reviewed from a personal perspective, including discussion of the most recent finding that two pathways to B₁₂ existone aerobic and one anaerobicwhich differ mainly in the ring contraction mechanisms that convert porphyrin to corrin.

View: Full Text HTML | Hi-Res PDF

Tools

SciFinder Links

History

Published In Issue April 04, 2003
Received December 6, 2002

Recommend & Share

Related Content

The benzodiazepine storyJournal of Medicinal Chemistry
- The benzodiazepine story
  Leo H. Sternbach
  Journal of Medicinal Chemistry 1979 22 (1), pp 1–7
  Abstract | Hi-Res PDF
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonistsJournal of Medicinal Chemistry
- Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists
  B. E. Evans, K. E. Rittle, M. G. Bock, R. M. DiPardo, R. M. Freidinger, W. L. Whitter, G. F. Lundell, D. F. Veber, P. S. Anderson,
  Journal of Medicinal Chemistry 1988 31 (12), pp 2235–2246
  Abstract | Hi-Res PDF
A Scaleable Synthesis of FiduxosinOrganic Process Research & Development
- A Scaleable Synthesis of Fiduxosin
  Anthony R. Haight, Anne E. Bailey, William S. Baker, Michael H. Cain, Richard R. Copp, John A. DeMattei, Kelley L. Ford, Rodger F. Henry, Margaret C. Hsu, Robert F. Keyes, Steven A. King, Maureen A. McLaughlin, Laura M. Melcher, William R. Nadler, Patricia A. Oliver, Shyamal I. Parekh, Hemant H. Patel, Louis S. Seif, Mike A. Staeger, Gregory S. Wayne, Steven J. Wittenberger, and Weijiang Zhang
  Organic Process Research & Development 2004 8 (6), pp 897–902
  Abstract: Fiduxosin (1) has been under development at Abbott Laboratories for the treatment of benign prostatic hyperplasia. A convergent strategy required methodologies for preparation of an enantiomerically pure 3,4-cis-disubstituted pyrrolidine and a 2,3,5-...
  Abstract | Full Text HTML | Hi-Res PDF

Perspective

Discovering Nature's Diverse Pathways to Vitamin B₁₂: A 35-Year Odyssey